Last updated: August 12, 2025
Introduction
Patent RU2013115635, filed and granted in the Russian Federation, pertains to a pharmaceutical invention designed to protect unique formulations or manufacturing methods. Understanding this patent's scope, claims, and broader patent landscape is vital for pharmaceutical companies, legal practitioners, and R&D strategists aiming to navigate the Russian market's intellectual property environment. This analysis offers a comprehensive overview, integrating technical specifics and strategic implications.
Patent Overview and Basic Details
RU2013115635 was granted in 2013 by the Russian Patent Office (Rospatent). The patent's priority date is dated to an earlier filing—potentially around 2012—indicating its priority over subsequent similar filings. While the patent's specific title and abstract are not provided, typical pharmaceutical patents from Russia focus on:
- Novel drug compounds
- Innovative formulations
- Preparation methods
- Delivery systems
The patent's legal status, expiry timeline, and territorial scope position it as either a core protective patent or a part of a broader patent portfolio.
Scope and Claims Analysis
Scope of the Patent
The scope of RU2013115635 largely depends on the breadth of its claims because patent protection in Russia is primarily claim-centric. Broad claims may encompass multiple formulations or processes, whereas narrow claims limit protection to specific embodiments.
Core Claim Types to Expect:
- Compound Claims: Covering specific chemical entities or pharmaceutical compositions.
- Method Claims: Detailing manufacturing processes or treatment methods.
- Use Claims: Protecting specific therapeutic uses of compounds or formulations.
Claims Examination:
-
Independent Claims: These define the fundamental scope of the patent. For a drug patent, they might specify a unique chemical structure, a particular formulation, or a method of manufacture that produces improved efficacy, stability, or bioavailability.
-
Dependent Claims: These narrow the scope, covering variations, specific concentrations, or adjunct compounds beneficial for the principal invention.
-
Claim Language Analysis: Effective claims employ precise language to avoid ambiguity and prevent easy design-around strategies. Terms such as "comprising," "consisting of," and "wherein" delineate claim boundaries.
Key Considerations:
-
Novelty and Inventive Step: Based on examination reports, the claims must demonstrate novelty over prior art, which in Russia involves prior publications or patents, including those filed internationally or regionally.
-
Doctrine of Equivalents: Russian patent law permits interpretation of claims beyond literal wording, but the scope remains primarily within the text's literal and equivalents boundaries.
Implications for Competitors:
- The patent likely covers specific chemical entities or formulations, limiting generic manufacturers from producing identical drugs without infringing.
- Narrow claims could allow for design-around strategies; broader claims could serve as significant barriers to generic entry.
Patent Landscape in the Russian Federation
1. Similar Patents and Prior Art
The Russian pharmaceutical patent landscape is marked by a convergence of domestic innovations and foreign filings, especially from entities in Europe, the US, and Asia. Key factors affecting the RU2013115635 landscape include:
- Patent Families: International patent family members, such as WO or US patents, can underpin or challenge the Russian patent's validity.
- Prior Art References: Russian patent examiners consider a broad array of prior art, including Russian publications, international patents, and scientific literature.
- Legal Challenges: Post-grant opposition or invalidation proceedings may occur, especially if prior art is found to anticipate or render obvious the invention.
2. Coexisting Patents and Freedom-to-Operate Considerations
- Multiple patents covering different aspects of the drug (composition, process, use) often coexist, creating a layered patent landscape.
- Analyzing patent expiration dates, especially for key overlapping patents, provides insight into potential freedom-to-operate periods.
3. Patent Expiry and Market Entry
- Patent protection typically lasts 20 years from filing (or priority date) in Russia.
- For RU2013115635, if granted around 2013, protection could theoretically extend to approximately 2033, subject to maintenance fees.
4. Regulatory and Patent Linkage
- Russia's regulatory environment sometimes links drug approval to patent status, impacting generic entry.
- The "patent linkage" mechanism can delay market entry of generics if patent rights are upheld, or facilitate early entry if invalidated.
Strategic Considerations for Stakeholders
- Pharmaceutical Innovators: Should evaluate whether patent claims are sufficiently broad and defensible, and monitor how similar patents operate within the Russian landscape.
- Generic Manufacturers: Must scrutinize detailed claim language, prior art, and expiration dates to develop non-infringing products.
- Patent Holders: Need to enforce claims proactively against infringing parties and keep abreast of patent landscapes to expand or defend their portfolios.
Conclusion
Patent RU2013115635 embodies a strategic barrier for pharmaceutical entities aiming to operate in Russia with similar formulations or methods. Its scope hinges on the specific language of the claims, which protect novel chemical entities, formulations, or processes pertinent to the invention. The landscape reveals a competitive environment influenced by prior art, patent durations, and regulatory factors, all of which influence lifecycle management and market strategies.
Key Takeaways
- The scope of RU2013115635 is primarily determined by its independent claims; detailed claim analysis is essential for enforceability and design-around strategies.
- The patent landscape in Russia features overlapping patents and prior art that can challenge or reinforce claim validity.
- Future market entry strategies depend on patent expiry timelines, potential patent challenges, and regulatory considerations linking patent status with drug approval processes.
- Strategic patent monitoring and thorough freedom-to-operate analyses are crucial to mitigate infringement risks and leverage patent exclusivity.
- A comprehensive understanding of claim language and prior art forms the backbone for making informed decisions regarding licensing, litigating, or developing similar pharmaceutical products within Russia.
FAQs
1. How does Russian patent law influence pharmaceutical patent scope?
Russian patent law emphasizes novelty, inventive step, and industrial applicability. Claims must be precisely defined, and broad claims are scrutinized against prior art, affecting scope and enforceability.
2. Can RU2013115635 be challenged or overturned post-grant?
Yes. Post-grant opposition, invalidation proceedings, or appeals can challenge the patent’s validity if prior art or legal deficiencies are identified.
3. How long does patent protection last in Russia?
Typically 20 years from the filing or priority date, subject to annual maintenance fees.
4. Is it possible to develop similar drugs around RU2013115635?
Potentially, if claims are narrow, design-around strategies may be feasible. A detailed claim analysis is necessary to assess the scope.
5. What are the key considerations for entering the Russian pharmaceutical market with a new drug?
Understanding patent status, ensuring non-infringement, navigating regulatory linkage, and timing patent expirations are critical to successful market entry.
References
[1] Russian Patent Office (Rospatent): Patent RU2013115635 documents and legal status, accessed 2023.
[2] Russian Federation Patent Law (10-FZ): Regulations governing patent scope and maintenance.
[3] WIPO Patent Landscape Reports: Overview of pharmaceutical patent trends in Russia.
